Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: Basic and clinical aspects

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 4, 2002, Pages 539-548

  Kato, Hisao ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Blood coagulation; Restenosis; Thrombosis; Tissue factor pathway inhibitor; Vascular wall cells

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; PLASMIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLOOD CLOTTING; ENDOTHELIUM CELL; GENE TRANSFER; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOGENESIS; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD COAGULATION; CELL DIVISION; ENDOTHELIUM, VASCULAR; FACTOR VIIA; FACTOR XA; HUMANS; LIPOPROTEINS; MICE; MICE, KNOCKOUT; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 0036120686     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000013904.40673.CC     Document Type: Short Survey

References (121)

1. Regulation of blood coagulation by protease inhibitors
2. Tissue factor pathway inhibitor (TFPI): An update
3. Tissue factor pathway inhibitor: From unknown coagulation inhibitor to major antithrombotic principle
4. Tissue factor pathway inhibitor
5. Tissue factor pathway inhibitor
6. Structure and biology of tissue factor pathway inhibitor
7. Cloning and characterization of cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
8. A novel degradation pathway of tissue factor pathway inhibitor: Incorporation into fibrin clot and degradation by thrombin
9. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: Effect on TFPI activity
10. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity
11. Matrix metalloproteinases cleave tissue factor pathway inhibitor: Effects on coagulation
12. Structure of extracellular tissue factor complexed with factor VIIa with a BPTI mutant
13. The second Kunitz domain of human TFPI: Cloning, structure determination and interaction with factor Xa
14. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor
15. Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor
16. Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction
17. Evolutionary origin of a Kunitz-type trypsin inhibitor domain inserted in the amyloid beta precursor protein of Alzheimer's disease
18. Monkey hepatocytes efficiently express tissue factor pathway inhibitor (TFPI), in contrast with human and rat hepatocytes
19. Tissue factor pathway inhibitor production by human mesangial cells in culture
20. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors
21. Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages: Relationship to tissue factor induction by cholesterol and oxidized LDL
22. Regulation of tissue factor pathway inhibitor expression in smooth muscle cells
23. Synthesis and expression of tissue factor pathway inhibitor by serum-stimulated fibroblasts, vascular smooth muscle cells and cardiomyocytes
24. Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukapheresis and elutriation: Response of nonadherent cells to lipopolysaccharide
25. Lysophosphatidylcholine decreases the synthesis of tissue factor pathway inhibitor in human umbilical vein endothelial cells
26. Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignants cells
27. Production of tissue factor pathway inhibitor in cardiomyocytes and its upregulation by interleukin-1
28. Heterogeneity of plasma tissue factor pathway inhibitor
29. Down-regulation of monocyte tissue factor-mediated by TFPI and LRP
30. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor
31. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor
32. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway
33. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae: Regulatory mechanism(s) of the anticoagulant properties of the endothelium
34. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor
35. Binding of tissue factor pathway inhibitor to cultures endothelial cells-influence of glycosaminoglycans
36. Tissue factor pathway inhibitor binds to platelet thrombospondin-1
37. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture
38. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons
39. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro
40. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture
41. Recombinant full-length tissue factor pathway inhibitor fails to bind to the cell surface: Implications for catabolism in vitro and in vivo
42. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1
43. A comparative study of functional assay for tissue factor pathway inhibitor using normal plasma and clinical samples
44. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease
45. Development of a method to separate lipoprotein-bound and lipoproteindepleted tissue factor pathway inhibitor: Measurement of free tissue factor pathway inhibitor activity
46. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: Its characterization and application to plasmas from patients with disseminated intravascular coagulation
47. Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo
48. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction
49. Circadian variation in plasma levels of free-form tissue factor pathway inhibitor antigen in patients with coronary spastic angina
50. Heparin-releasable endothelial cell-associated tissue factor pathway inhibitor (TFPI) is increased in the coronary circulation after coronary spasm in patients with coronary spastic angina
51. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris
52. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina
53. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease
54. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients
55. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation
56. Comparison of the inhibitory effects of apoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation
57. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase proportional to apolipoprotein A-II
58. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers
59. Imbalance of plasminogen activator inhibitor-1/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction
60. A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L]TFPI
61. The 536C-T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis
62. The TFPI C536T mutation is not associated with increased risk for venous or arterial thrombosis
63. Polymorphism of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI
64. No link between the TFPI V264M mutation and venous thromboembolic disease
65. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty
66. C-399 polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasm TFPI antigen level and does not cause venous thrombosis
67. Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells
68. Human recombinant tissue factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells
69. Carboxyl terminal basic amino acid region of TFPI prevents proliferation of human smooth muscle cells by inhibiting activation of MAP kinase kinase (MEK 1/2)
70. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity
71. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis
72. Expression, localization and activity of TFPI in normal and atherosclerotic human vessels
73. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor a expression by inducing Elk-1 phosphorylation and Egr-1 expression
74. Regulation of monocyte procoagulant activity in acute myocardial infarction: Role of tissue factor and tissue factor pathway inhibitor-1
75. Regulation of monocyte procoagulant activity in acute myocardial infarction: Role of tissue factor and tissue factor pathway inhibitor-1
76. Oxidized low-density lipoprotein impairs the anticoagulant function of tissue factor pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells
77. Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation
78. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: A novel link between lipoproteins and thrombosis
79. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor
80. Role of coagulation inhibitors in inflammation
81. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex
82. Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins
83. Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins
84. Overexpression of tissue factor pathway inhibitor in aortic smooth muscle cells inhibits migration induced by tissue factor/factor VIIa complex
85. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14
86. Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: Concerted effect with antithrombin
87. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
88. Local irrigation with tissue factor pathway inhibitors inhibits intimal hyperplasia induced by arterial interventions
89. Fibrin-rich and platelet-rich thrombus formation on neointima: Recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta
90. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulated of tissue factor at the site of balloon-induced arterial injury in pigs
91. Comparison of methods for local delivery of tissue factor pathway inhibitor to balloon-injured arteries in rabbits
92. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat
93. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury
94. Adenoviruss-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit
95. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human TFPI
96. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries
97. Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts
98. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty
99. Topically applied tissue factor pathway inhibitor reduced intimal thickness of small arterial autografts in rabbits
100. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries
101. Role for tissue factor pathway in murine model of vascular remodeling
102. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with very low density lipoprotein receptor
103. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice
104. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit
105. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice
106. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
107. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during endotoxemia
108. Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock
109. Antibodies to β2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor
110. Syndecan-4 deficiency impairs focal adhesion formation only under restricted conditions
111. Syndecan-4 deficiency leads to high mortality of lipopolysaccharideinjected mice
112. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: Identification as placental protein 5 and tissue factor pathway inhibitor-2
113. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor
114. Cloning of the cDNA encoding murine PP5/TFPI-2 and mapping of the gene to chromosome 6
115. Inhibitory properties of human recombinant Arg24->Gln type-2 tissue factor pathway inhibitor (R24Q TFPI-2)
116. Nucleotide sequence of the gene encoding murine tissue factor pathway inhibitor-2
117. Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells
118. Matrix localization of tissue factor pathway inhibitor-2/matorix-associated serine proteinase inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: Heparin accelerates the activity of TFPI-2/MSPI toward plasmin
119. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinases-2 and is down-regulated in cells harboring activated ras oncogenes
120. Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells
121. Prokaryotic expression, purification, and reconstitution of biological activities (antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2